Investor Relations

W e are a clinical-stage biopharmaceutical company focused on developing innovative medicines. Founded in 2020 and based in Shanghai, Changshu, and Suzhou, China, we are primarily dedicated to the in-house discovery and development of biologics for allergic and autoimmune diseases. Powered by our proprietary technology platform and strong R&D capabilities, we are advancing a broad pipeline of biologic therapies across rhinology, dermatology, respiratory medicine, hematology, nephrology, and other autoimmune disease areas.

LongBio Pharma aims to work with our partners to bring our medicines to both domestic and international markets, especially to deliver more affordable, high-quality biologics to patients.